FDA launches pilot to speed up early drug trials and bolster U.S. competitiveness
The FDA announced a pilot to accelerate early-stage clinical trials, aiming to cut development time by six to 12 months, boost U.S.-based trials, and counter China, while seeking congressional support to establish a permanent, faster Investigational New Drug pathway in the 2027 budget; the effort follows advocacy by former FDA Commissioner Marty Makary.